Athenex Investor Relations Material

Athenex, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel cancer therapies. The company operates through two primary segments: the Oncology Innovation Platform and the Commercial Platform. Its research and development efforts are centered around proprietary cell therapy technologies, including its Natural Killer T-cell (NKT) therapy, aimed at treating cancer. Athenex also manages a commercial division that markets specialty pharmaceutical products, particularly in oncology and related fields. The company is headquartered in Buffalo, New York, and its shares are listed on the OTC market.